Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Cellular Thermal Shift Assay (CETSA®)

Our biophysicists can incorporate the use of the CETSA® platform into your integrated project via our alliance with Pelago Bioscience. The CETSA® platform provides a label free physiologically relevant measure of affinity allowing the demonstration of direct target engagement. Pelago Bioscience, founded by the inventor of CETSA® platform, is the industry leader in the application of the CETSA® to study target engagement.

CETSA® involves heating cell lysates to different temperatures and quantifying the presence of target protein in the soluble fraction by western blotting or mass spectrometry. It is suitable for studying target engagement in lysates, intact cells and tissue and is applicable to a wide range of soluble intracellular and extracellular drug targets, capable of resolving potencies from mM to fM.

A typical protein melting curve generated by CETSA® analysis in order to study protein-ligand interactions

  • Quantitative measure of target engagement
  • Physiologically relevant readout of affinity
  • Suitable for lysates, intact cells and tissue
  • Applicable to a wide range of soluble intracellular and extracellular drug targets as well as membrane protein targets
  • Monitor target specificity, drug transport and activation
  • Label free

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

Areas of interest

Discovery Discipline
Therapeutic Areas
The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.